This company has been marked as potentially delisted and may not be actively trading.

R1 RCM (RCM) Competitors

RCM vs. LH, DGX, DVA, CHE, and CRVL

Should you be buying R1 RCM stock or one of its competitors? The main competitors of R1 RCM include Labcorp (LH), Quest Diagnostics (DGX), DaVita (DVA), Chemed (CHE), and CorVel (CRVL). These companies are all part of the "health care services" industry.

How does R1 RCM compare to Labcorp?

Labcorp (NYSE:LH) and R1 RCM (NASDAQ:RCM) are both health care services companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

: Labcorp presently has a consensus target price of $308.00, suggesting a potential upside of 19.77%. Given Labcorp's stronger consensus rating and higher possible upside, analysts clearly believe Labcorp is more favorable than R1 RCM.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Labcorp
0 Sell rating(s)
3 Hold rating(s)

8 Buy rating(s)

0 Strong Buy rating(s)
2.73
R1 RCM
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Labcorp has higher revenue and earnings than R1 RCM. R1 RCM is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Labcorp $13.95B 1.51 $876.50M $11.29 22.78
R1 RCM $2.25B 2.68 $3.30M -$0.15 N/A
: Labcorp has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, R1 RCM has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.
: 95.9% of Labcorp shares are held by institutional investors. Comparatively, 61.1% of R1 RCM shares are held by institutional investors. 0.8% of Labcorp shares are held by company insiders. Comparatively, 36.8% of R1 RCM shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: In the previous week, Labcorp had 25 more articles in the media than R1 RCM. MarketBeat recorded 25 mentions for Labcorp and 0 mentions for R1 RCM. R1 RCM's average media sentiment score of 0.76 beat Labcorp's score of 0.75 indicating that R1 RCM is being referred to more favorably in the news media.
Company Overall Sentiment
Labcorp Positive
R1 RCM Positive
: Labcorp has a net margin of 6.66% compared to R1 RCM's net margin of -2.48%. Labcorp's return on equity of 16.29% beat R1 RCM's return on equity.
Company Net Margins Return on Equity Return on Assets
Labcorp 6.66% 16.29% 7.62%
R1 RCM -2.48% -2.18% -1.10%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Labcorp	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
R1 RCM	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Labcorp	$13.95B	1.51	$876.50M	$11.29	22.78
R1 RCM	$2.25B	2.68	$3.30M	-$0.15	N/A

Company	Overall Sentiment
Labcorp	Positive
R1 RCM	Positive

Company	Net Margins	Return on Equity	Return on Assets
Labcorp	6.66%	16.29%	7.62%
R1 RCM	-2.48%	-2.18%	-1.10%

Summary

Labcorp beats R1 RCM on 13 of the 16 factors compared between the two stocks.

How does R1 RCM compare to Quest Diagnostics?

R1 RCM (NASDAQ:RCM) and Quest Diagnostics (NYSE:DGX) are both health care services companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

: Quest Diagnostics has a consensus target price of $214.54, suggesting a potential upside of 12.42%. Given Quest Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Quest Diagnostics is more favorable than R1 RCM.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
R1 RCM
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Quest Diagnostics
0 Sell rating(s)

8 Hold rating(s)

7 Buy rating(s)

0 Strong Buy rating(s)
2.47
: Quest Diagnostics has higher revenue and earnings than R1 RCM. R1 RCM is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
R1 RCM $2.25B 2.68 $3.30M -$0.15 N/A
Quest Diagnostics $11.04B 1.91 $992M $9.05 21.09
: R1 RCM has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Quest Diagnostics has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.
: 61.1% of R1 RCM shares are held by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are held by institutional investors. 36.8% of R1 RCM shares are held by insiders. Comparatively, 0.9% of Quest Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: In the previous week, Quest Diagnostics had 13 more articles in the media than R1 RCM. MarketBeat recorded 13 mentions for Quest Diagnostics and 0 mentions for R1 RCM. Quest Diagnostics' average media sentiment score of 1.27 beat R1 RCM's score of 0.76 indicating that Quest Diagnostics is being referred to more favorably in the news media.
Company Overall Sentiment
R1 RCM Positive
Quest Diagnostics Positive
: Quest Diagnostics has a net margin of 9.07% compared to R1 RCM's net margin of -2.48%. Quest Diagnostics' return on equity of 15.60% beat R1 RCM's return on equity.
Company Net Margins Return on Equity Return on Assets
R1 RCM -2.48% -2.18% -1.10%
Quest Diagnostics 9.07% 15.60% 7.06%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
R1 RCM	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Quest Diagnostics	0 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.47

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
R1 RCM	$2.25B	2.68	$3.30M	-$0.15	N/A
Quest Diagnostics	$11.04B	1.91	$992M	$9.05	21.09

Company	Overall Sentiment
R1 RCM	Positive
Quest Diagnostics	Positive

Company	Net Margins	Return on Equity	Return on Assets
R1 RCM	-2.48%	-2.18%	-1.10%
Quest Diagnostics	9.07%	15.60%	7.06%

Summary

Quest Diagnostics beats R1 RCM on 13 of the 16 factors compared between the two stocks.

How does R1 RCM compare to DaVita?

R1 RCM (NASDAQ:RCM) and DaVita (NYSE:DVA) are both health care services companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

: In the previous week, DaVita had 15 more articles in the media than R1 RCM. MarketBeat recorded 15 mentions for DaVita and 0 mentions for R1 RCM. R1 RCM's average media sentiment score of 0.76 beat DaVita's score of 0.72 indicating that R1 RCM is being referred to more favorably in the media.
Company Overall Sentiment
R1 RCM Positive
DaVita Positive
: 61.1% of R1 RCM shares are held by institutional investors. Comparatively, 90.1% of DaVita shares are held by institutional investors. 36.8% of R1 RCM shares are held by insiders. Comparatively, 1.5% of DaVita shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: DaVita has a net margin of 5.47% compared to R1 RCM's net margin of -2.48%. R1 RCM's return on equity of -2.18% beat DaVita's return on equity.
Company Net Margins Return on Equity Return on Assets
R1 RCM -2.48% -2.18% -1.10%
DaVita 5.47% -413.18% 4.70%
: DaVita has higher revenue and earnings than R1 RCM. R1 RCM is trading at a lower price-to-earnings ratio than DaVita, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
R1 RCM $2.25B 2.68 $3.30M -$0.15 N/A
DaVita $13.64B 0.77 $746.80M $9.91 15.84
: DaVita has a consensus target price of $155.80, suggesting a potential downside of 0.75%. Given DaVita's stronger consensus rating and higher probable upside, analysts clearly believe DaVita is more favorable than R1 RCM.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
R1 RCM
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
DaVita
1 Sell rating(s)

5 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: R1 RCM has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, DaVita has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.

Company	Overall Sentiment
R1 RCM	Positive
DaVita	Positive

Company	Net Margins	Return on Equity	Return on Assets
R1 RCM	-2.48%	-2.18%	-1.10%
DaVita	5.47%	-413.18%	4.70%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
R1 RCM	$2.25B	2.68	$3.30M	-$0.15	N/A
DaVita	$13.64B	0.77	$746.80M	$9.91	15.84

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
R1 RCM	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
DaVita	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

DaVita beats R1 RCM on 11 of the 15 factors compared between the two stocks.

How does R1 RCM compare to Chemed?

R1 RCM (NASDAQ:RCM) and Chemed (NYSE:CHE) are both mid-cap health care services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

: 61.1% of R1 RCM shares are held by institutional investors. Comparatively, 95.9% of Chemed shares are held by institutional investors. 36.8% of R1 RCM shares are held by insiders. Comparatively, 3.3% of Chemed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
: Chemed has a consensus target price of $501.50, indicating a potential upside of 17.21%. Given Chemed's stronger consensus rating and higher possible upside, analysts plainly believe Chemed is more favorable than R1 RCM.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
R1 RCM
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Chemed
0 Sell rating(s)

4 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
: R1 RCM has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, Chemed has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.
: In the previous week, Chemed had 11 more articles in the media than R1 RCM. MarketBeat recorded 11 mentions for Chemed and 0 mentions for R1 RCM. R1 RCM's average media sentiment score of 0.76 beat Chemed's score of 0.55 indicating that R1 RCM is being referred to more favorably in the media.
Company Overall Sentiment
R1 RCM Positive
Chemed Positive
: Chemed has higher revenue and earnings than R1 RCM. R1 RCM is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
R1 RCM $2.25B 2.68 $3.30M -$0.15 N/A
Chemed $2.53B 2.24 $265.24M $18.35 23.32
: Chemed has a net margin of 10.23% compared to R1 RCM's net margin of -2.48%. Chemed's return on equity of 27.18% beat R1 RCM's return on equity.
Company Net Margins Return on Equity Return on Assets
R1 RCM -2.48% -2.18% -1.10%
Chemed 10.23% 27.18% 17.38%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
R1 RCM	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Chemed	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Overall Sentiment
R1 RCM	Positive
Chemed	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
R1 RCM	$2.25B	2.68	$3.30M	-$0.15	N/A
Chemed	$2.53B	2.24	$265.24M	$18.35	23.32

Company	Net Margins	Return on Equity	Return on Assets
R1 RCM	-2.48%	-2.18%	-1.10%
Chemed	10.23%	27.18%	17.38%

Summary

Chemed beats R1 RCM on 12 of the 16 factors compared between the two stocks.

How does R1 RCM compare to CorVel?

CorVel (NASDAQ:CRVL) and R1 RCM (NASDAQ:RCM) are both mid-cap business services companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

: 51.4% of CorVel shares are owned by institutional investors. Comparatively, 61.1% of R1 RCM shares are owned by institutional investors. 44.6% of CorVel shares are owned by company insiders. Comparatively, 36.8% of R1 RCM shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CorVel
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
R1 RCM
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: CorVel has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, R1 RCM has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.
: In the previous week, CorVel had 1 more articles in the media than R1 RCM. MarketBeat recorded 1 mentions for CorVel and 0 mentions for R1 RCM. CorVel's average media sentiment score of 0.84 beat R1 RCM's score of 0.76 indicating that CorVel is being referred to more favorably in the media.
Company Overall Sentiment
CorVel Positive
R1 RCM Positive
: CorVel has higher earnings, but lower revenue than R1 RCM. R1 RCM is trading at a lower price-to-earnings ratio than CorVel, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CorVel $895.59M 3.26 $95.17M $2.04 27.98
R1 RCM $2.25B 2.68 $3.30M -$0.15 N/A
: CorVel has a net margin of 11.23% compared to R1 RCM's net margin of -2.48%. CorVel's return on equity of 30.15% beat R1 RCM's return on equity.
Company Net Margins Return on Equity Return on Assets
CorVel 11.23% 30.15% 17.62%
R1 RCM -2.48% -2.18% -1.10%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorVel	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
R1 RCM	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Overall Sentiment
CorVel	Positive
R1 RCM	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorVel	$895.59M	3.26	$95.17M	$2.04	27.98
R1 RCM	$2.25B	2.68	$3.30M	-$0.15	N/A

Company	Net Margins	Return on Equity	Return on Assets
CorVel	11.23%	30.15%	17.62%
R1 RCM	-2.48%	-2.18%	-1.10%

Summary

CorVel beats R1 RCM on 12 of the 14 factors compared between the two stocks.

Get R1 RCM News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RCM vs. The Competition

Export

Metric	R1 RCM	Management services Industry	Business Sector	NASDAQ Exchange
Market Cap	$6.04B	$4K	$6.40B	$11.77B
Dividend Yield	N/A	N/A	3.07%	5.26%
P/E Ratio	-95.39	N/A	21.41	23.23
Price / Sales	2.68	0.01	431.77	75.49
Price / Cash	20.89	N/A	23.12	53.90
Price / Book	2.15	N/A	5.84	6.69
Net Income	$3.30M	-$1.06M	$200.90M	$332.64M

R1 RCM Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RCM R1 RCM	N/A	$14.31 flat	N/A	N/A	$6.04B	$2.25B	N/A	30,000
LH Labcorp	4.5976 of 5 stars	$257.87 +1.9%	$308.00 +19.4%	N/A	$21.18B	$14.14B	22.83	71,000	Earnings Report Analyst Upgrade
DGX Quest Diagnostics	4.8107 of 5 stars	$191.08 -0.2%	$214.54 +12.3%	N/A	$21.15B	$11.28B	21.11	57,000	Positive News Analyst Upgrade
DVA DaVita	2.9047 of 5 stars	$155.47 +0.9%	$155.80 +0.2%	N/A	$10.33B	$13.64B	15.61	78,000	Trending News Earnings Report
CHE Chemed	4.8286 of 5 stars	$429.05 +0.7%	$501.50 +16.9%	N/A	$5.69B	$2.53B	23.38	15,811	News Coverage Analyst Upgrade Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RCM) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

R1 RCM (RCM) Competitors